3 HER-2/neu Gene amplification and protein overexpression in breast carcinoma. immunohistochemistry and fluorescence in situ hybridization

Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas

Volumn 1, Issue , 2002, Pages 259-265

  Ooi, Akishi ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33748604618     PISSN: 18745784     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1874-5784(04)80037-0     Document Type: Chapter

References (22)

1. Bartlett J., Mallon E., and Cooke T. The clinical evaluation of HER-2 status: Which test to use?. J. Pathol. 199 (2003) 411-417
2. Coene E.D., Schelfhout V., Winkler R.A., Schelfout A.M., Van Roy N., Grooteclaes M., Speleman F., and De Potter C.R. Amplification units and translocation at chromosome 17q and c-erbB-2 overexpression in the pathogenesis of breast cancer. Virch. Arch. 430 (1997) 365-372
3. Couturier J., Vincent-Salomon A., Nicolas A., Beuzeboc P., Mouret E., Zafrani B., and Sastre-Garau X. Strong correlation between results of fluorescent in situ hybridization and immunohistoehemistry for the assessment of the ERBB2 (HER-2/neu) gene status i. Mod. Pathol. 13 (2000) 1238-1243
4. Fried M., Feo S., and Heard E. The role of inverted duplication in the generation of gene amplification in mammalian cells. Biochim. Biophys. Acta 1090 (1991) 143-155
5. Glockner S., Buurman H., Kleeberger W., Lehmann U., and Kreipe H. Marked intramoral heterogeneity of c-myc and cyclinDl but not of c-erbB2 amplification in breast cancer. Lab. Invest. 82 (2002) 1419-1426
6. Hara T., Ooi A., Kobayashi M., Mai M., Yanagihara K., and Nakanishi I. Amplification of C-Myc, K-sam, and c-met in gastric cancers: Detection by fluorescence in situ hybridization. Lab. Invest. 78 (1998) 1143-1153
7. Ishikawa T., Kobayashi M., Mai M., Suzuki T., and Ooi A. Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. Am. J. Pathol. 151 (1998) 761-768
8. Jacobs T.W., Gown A.M., Yaziji H., Barnes M.J., and Schnitt S.J. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J. Clin. Oncol. 77 (1999) 1974-1982
9. Kitayama Y., Igarashi H., and Sugimura H. Initial intermittent microwave irradiation for fluorescence in situ hybridization analysis in paraffin-embedded tissue sections of gastrointestinal neopla. Lab. Invest. 80 (2000) 779-781
10. Kobayashi M., Ooi A., Oda Y., and Nakanishi I. Protein overexpression and gene amplification of c-erbB-2 in breast carcinomas: A comparative study of immunohistoehemistry and fluorescence in situ hybri. Hum. Pathol. 33 (2002) 21-28
11. Kunitomo K., Takehana T., Inoue S., Fujii H., Suzuki S., Matsumoto Y., and Ooi A. Detection of c-erbB-2 (HER-2/neu) amplification in breast carcinoma by fluorescence in situ hybridization on tissue sections and imprinted cells. Pathol. Int. 53 (2002) 451-457
12. In Press. Kunitomo M., Inoue S., Ichihara F., Kono K., Fujii H., Matsumoto Y., and Ooi A. A case of metastatic breast cancer with outgrowth of HER-2-negative cells after eradication of HER-2-positive cells by humanized anti-HER-2 monoclonal antibod. Hum. Pathol. (2003)
13. Mitelman F. Catalog of Chromosome Aberrations in Cancer. 5th ed (1994), New York
14. Press M.F., Hung G., Godolphin W., and Slamon D.J. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 54 (1994) 2771-2777
15. Ruiz J.C., and Wahl G.M. Chromosomal destabilization during gene amplification. Mol. Cell. Biol. 10 (1990) 3056-3066
16. Simon R., Nocito A., Hubscher T., Bucher C., Torhorst J., Schraml P., Bubendorf L., Mihatsch M.M., Moch H., Wilber K., Schotzau A., Kononen J., and Sauter G. Patterns of Her-2/neu amplification and overexpression in primary and metastatic breat cancer. J. Natl. Cancer Inst. 93 (2001) 1141-1146
17. Slamon D.J., Clark G.M., Wong S., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
18. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., and Norton L. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2. N. Engl. J. Med. 344 (2001) 783-792
19. Takehana T., Kunitomo K., Kono K., Kitahara F., Iizuka H., Matsumoto Y., Fujino M.A., and Ooi A. Status of c-erbB-2 in gastric adenocarcinoma: A comparative study of immunohistochemistry, fluorescence in situ hybridization, and enzyme-linked immuno-so. Int. J. Cancer 98 (2002) 833-837
20. Thor A. Are patterns of HER-2/neu amplification and expression among primary tumors and regional metastases indicative of those in distant metastases and predictive o. J. Natl. Cancer Inst. 95 (2001) 1120-1121
21. Wang S., Saboorian M.H., Frenkel E., Hynan L., Gokaslan S.T., and Ashfaq R. Laboratory assessment of the status of HER-2/neu protein and oncogene in breast cancer specimens: Comparison of immunohistochemistry assay with fluorescence. J. Clin. Pathol. 53 (2000) 374-381
22. Xing W.R., Gilchrist K.W., Harris C.P., Samson W., and Meisner L.F. FISH detection of HER-2/neu oncogene amplification in early onset breast cancer. Breast Cancer Res. Treat 39 (1996) 203-212